Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tripchlorolide is a natural small molecule compound derived from the plant Tripterygium wilfordii, structurally related to triptolide and known as Triptolide 12,13-chlorohydrin.[2][5][8] It exhibits potent **antitumor**, **anti-inflammatory**, and **neuroprotective** properties. Mechanistically, tripchlorolide induces cell death in various cancer cell lines, particularly A549 lung cancer cells, primarily by activating autophagy through inhibition of the PI3K/AKT/mTOR signaling pathway rather than triggering apoptosis.[1][4][5] Preclinical evidence also suggests it modulates inflammatory and immune pathways, exerts neuroprotective effects (including protection against dopaminergic degeneration in Parkinson’s and cognitive deficits in Alzheimer’s models), and inhibits microglial activation via the STING-NLRP3 pathway.[5][7][10]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tripchlorolide.